How has been the historical performance of Alembic Pharma?

Answer:The historical performance of Alembic Pharma shows a consistent growth trend in net sales and operating profit over the years, with some fluctuations in profit margins and net profit.

Breakdown:
Alembic Pharma's net sales have increased from 3,934.68 Cr in March 2019 to 6,672.08 Cr in March 2025, reflecting a steady upward trajectory. The total operating income has similarly risen, reaching 6,672.08 Cr in March 2025 from 4,605.75 Cr in March 2020. The company's total expenditure has also grown, amounting to 5,663.84 Cr in March 2025, up from 3,061.10 Cr in March 2019. Operating profit (PBDIT) has shown fluctuations, peaking at 1,567.57 Cr in March 2021 before declining to 1,050.79 Cr in March 2025. Profit before tax reached 706.31 Cr in March 2025, while profit after tax was recorded at 581.14 Cr, down from 616.80 Cr in March 2024. The company's total assets have increased to 7,606.90 Cr in March 2025 from 5,989.05 Cr in March 2020, indicating growth in its asset base. However, total liabilities have also risen to 7,606.90 Cr in March 2025, up from 5,989.05 Cr in March 2020, primarily driven by an increase in short-term borrowings. Cash flow from operating activities has decreased significantly to 87.00 Cr in March 2025 from 1,463.00 Cr in March 2021, contributing to a net cash outflow of 36.00 Cr in March 2025. Overall, while Alembic Pharma has experienced growth in sales and assets, it faces challenges in maintaining profit margins and cash flow stability.